Skip to main content
Premium Trial:

Request an Annual Quote

WaveSense nRichDx

WaveSense has launched the nRichDx system for bulk isolation of target cells and nucleic acids from liquid biopsies. The new system uses WaveSense's proprietary paramagnetic bead technology to capture circulating tumor cells and cell-free DNA or RNA in quantities sufficient for subsequent next-generation sequencing or PCR analysis. The system can capture cells and nucleic acids from an array of sample types including blood, urine, and bone marrow, and is specifically designed and optimized for high-volume, low-yield specimens, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.